Rhinovirus Vaccine
AssigneeIP2Ipo Innovations Limited
InventorsSebastian Johnston, Stephen Shaw, Paul Hamblin, Aurelie Bornot, Piero Ricchiuto, Claus Bendtsen
Life of this patent
Estimating the term…
Abstract
The invention relates to immunogenic compositions, and in particular, to immunogenic compositions for preventing, treating or ameliorating human rhinovirus (RV) infections. The invention is especially concerned with RV VP0 peptides (or proteins) and polynucleotides encoding such peptides, and their use in immunogenic compositions for eliciting an immune response and preventing rhinovirus infections.
Claims10
1-21. (canceled)
An immunogenic composition comprising an isolated human rhinovirus peptide, or an isolated polynucleotide encoding the peptide, wherein the peptide comprises an amino acid sequence as set out in SEQ ID No:
- 13, or a variant or fragment thereof having at least 80% sequence identity to SEQ ID No:
- 13, and/or wherein the peptide is encoded by the nucleotide sequence as set out in SEQ ID No:
- 14, or a variant or fragment thereof having at least 80% sequence identity to SEQ ID No:
- 14.
Dependencies are inferred from the claim text.